Open Access

Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in vitro and in vivo via the epithelial‑to‑mesenchymal transition process

  • Authors:
    • Shanshan Jiang
    • Rong Wang
    • Xuan Zhang
    • Feihua Wu
    • Shengnan Li
    • Yongfang Yuan
  • View Affiliations

  • Published online on: April 15, 2020     https://doi.org/10.3892/ol.2020.11536
  • Pages: 346-356
  • Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Standard chemotherapy is commonly used in clinical practice for the treatment of non-small cell lung cancer (NSCLC). However, its therapeutic efficacy remains low. Combination therapy for cancer treatment has attracted attention in recent years. The present study aimed to investigate the antitumor effect of the combination treatment with gemcitabine and sorafenib on NSCLC in vitro and in vivo, and to determine its underlying molecular mechanisms. The anti‑NSCLC effects of combination therapy were analyzed by flow cytometry analysis, MTT, western blotting, reverse transcription‑quantitative PCR, wound healing and Transwell invasion assays. A549 cells subjected to combination treatment with gemcitabine and sorafenib demonstrated a more irregular cellular morphology and lower cell viability compared with the monotherapy groups. Combination of gemcitabine and sorafenib significantly induced cell cycle arrest and apoptosis in A549 cells. Additionally, combination therapy was demonstrated to restrain the migration and invasion of tumor cells by suppressing epithelial‑to‑mesenchymal transition (EMT) of A549 cells. In vivo analyses confirmed that co‑treatment with gemcitabine and sorafenib decreased NSCLC tumor growth and tumor weight in nude mice. Taken together, the results of the present study suggested that combination treatment with gemcitabine and sorafenib exerted a synergistic inhibitory effect on NSCLC in vitro and in vivo via the EMT process.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Jiang, S., Wang, R., Zhang, X., Wu, F., Li, S., & Yuan, Y. (2020). Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in vitro and in vivo via the epithelial‑to‑mesenchymal transition process. Oncology Letters, 20, 346-356. https://doi.org/10.3892/ol.2020.11536
MLA
Jiang, S., Wang, R., Zhang, X., Wu, F., Li, S., Yuan, Y."Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in vitro and in vivo via the epithelial‑to‑mesenchymal transition process". Oncology Letters 20.1 (2020): 346-356.
Chicago
Jiang, S., Wang, R., Zhang, X., Wu, F., Li, S., Yuan, Y."Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in vitro and in vivo via the epithelial‑to‑mesenchymal transition process". Oncology Letters 20, no. 1 (2020): 346-356. https://doi.org/10.3892/ol.2020.11536